302例他汀类药物相关肌肉系统损害的文献分析

摘要/Abstract

摘要： 目的研究他汀类药物相关肌肉系统损害在中国人群中的规律和特点,为临床合理用药提供参考。方法以“他汀”、“肌病”为关键词,检索中国知网全文数据库,根据纳入、排除标准对文献进行数据提取和分析。结果共纳入34篇文献,302例病例。辛伐他汀病例最多。共涉及8类严重药物相互作用。结论应合理选用他汀类药物,警惕药物相互作用并做好相关肌肉系统损害的处理和预防。

关键词: 他汀类药物相关肌肉系统损害, 药物相互作用, 文献分析

Abstract: Objective To provide references for rational medication through analyzing the characteristics of statin-induced muscular system disorders. Methods "Statin" and "myopathy" were used as keywords to search articles in CNKI database, then they were analyzed according to inclusion and exclusion criteria. Results A total of 34 articles were included, involving 302 cases. Simvastatin was the most common drug reported with myopathy. Eight kinds of drug-drug interaction were found. Conclusion It is important to choose proper statin and monitor drug interaction. More attention should be paid to treatment and prophylaxis of statin-induced muscular system disorders.

Key words: statin-induced musculer system disorders, drug interaction, literature analysis

中图分类号:

R994.11

高千秋, 张浩嘉. 302例他汀类药物相关肌肉系统损害的文献分析[J]. 中国药物警戒, 2018, 15(8): 476-480.

GAO Qianqiu, ZHANG Haojia. Literature Analysis of 302 Cases of Musuler System Disorders Induced by Statins[J]. Chinese Journal of Pharmacovigilance, 2018, 15(8): 476-480.

参考文献

[1] 诸骏仁, 高润霖, 赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 16(10):15-35.
[2] Kim K, Johnson J A, Derendorf H.Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms[J]. Journal of Clinical Pharmacology, 2013, 44(10):1083-1105.
[3] Liao J K.Safety and efficacy of statins in Asians[J]. American Journal of Cardiology, 2007, 99(3):410-414.
[4] 王佩, 刘恩生, 李玉珍. 辛伐他丁致药物性肌病[J]. 药物不良反应杂志, 1999, 1(1):50-51.
[5] 陈培莉, 赵全明, 徐予,等. 西立伐他汀、吉非贝齐合用引起严重横纹肌溶解症[J]. 药物不良反应杂志, 2001, 3(3):162-164.
[6] 李茂亭, 马娜. 辛伐他丁肌病二例报告[J]. 实用心脑肺血管病杂志, 2001, 9(2):90.
[7] 罗颂武. 舒降之引起肌病一例[J]. 今日药学, 2002, 12(4):49.
[8] 梅琪, 杨鲁渤, 范仰刚. 辛伐他汀致药源性肌病[J]. 药物不良反应杂志, 2003, 5(2):87.
[9] 黄立, 李红, 潘纬. 辛伐他汀与烟酸联用致严重肌病2例[J]. 川北医学院学报, 2004, 19(4):250-251.
[10] 李欣, 高鑫. 他汀类药物引起的肌病一例[J]. 中华全科医师杂志, 2004, 3(1):43-44.
[11] 李正业, 黄嵩, 曾波. 辛伐他汀与口服红霉素配伍致严重肌病8例[J]. 四川医学, 2004, 25(3):323.
[12] 魏子秀, 孙晓斐. 氟伐他汀与华法林合用导致肌病一例[J]. 中国循环杂志, 2004, 19(4):269.
[13] 周少丹, 汪瑜章. 阿托伐他汀(立普妥)致肌病一例[J]. 中国药师, 2005, 8(3):234-235.
[14] 刘晓凯. 辛伐他汀致肌病及急性肾功能不全一例报告[J]. 浙江临床医学, 2006, 8(1):85.
[15] 彭婕, 葛兆霞, 王颖捷. 口服辛伐他汀致肌病1例[J]. 药物流行病学杂志, 2007, 16(5):314.
[16] 苏前. 他汀类药物致肌病(附5例分析)[J]. 临床神经病学杂志, 2007, 20(4):58-59.
[17] 王宁, 陈海平. 他汀类药物致肌病的临床调查与分析[J]. 药物不良反应杂志, 2007, 9(6):384-387.
[18] 杨金彪. 口服辛伐他汀致肌病1例[J]. 中国药师, 2008, 11(1):85.
[19] 张松村, 刘辉. 辛伐他汀致多发肌炎1例报告[J]. 内蒙古中医药, 2008(4):39.
[20] 朱晓玲, 王素征. 阿托伐他汀致肌病1例[J]. 人民军医, 2008, 51(1):23.
[21] 韩毛毛, 应月华, 林小娟. 他汀类药物引起相关肌病2例的护理[J]. 护理与康复, 2010, 09(8):720-721.
[22] 唐浩军. 洛伐他汀致药物性肌病2例分析[J]. 内蒙古中医药, 2010, 29(8):46.
[23] 丁荣晶, 马丽. 辛伐他汀合用帕罗西汀致急性肝损害及肌病1例[J]. 中国新药杂志, 2011(15):1476-1477.
[24] 刘峰, 刘锐锋. 辛伐他汀致肝功能异常和肌病1例[J]. 中国药物警戒, 2012, 9(6):379.
[25] 李小玉, 张赟, 刘玉兰. 普伐他汀致老年患者横纹肌溶解症[J]. 药物不良反应杂志, 2012, 14(4):263-266.
[26] 王斌, 刘桂花. 辛伐他汀导致肝损害和肌病1例[J]. 中国临床药理学杂志, 2012, 28(1):62-63.
[27] 徐鹏, 张国柱. 他汀类药物相关性肌病及肝损害的药学监护[J]. 安徽医药, 2013, 17(1):150-151.
[28] 游俊丽, 范书英. 他汀性肌病两例并文献复习[J]. 中国全科医学, 2013, 16(2):221-224.
[29] 李艺, 张亚同. 临床药师参与1例普伐他汀致肌炎的药学实践[J]. 临床药物治疗杂志, 2014, 12(4):54-56.
[30] 马伟伟. 辛伐他汀致横纹肌溶解症1例并文献复习[J]. 实用医药杂志, 2014, 31(11):996-998.
[31] 肖滨. 他汀类药物治疗后疑似引起肌病1例[J]. 中国乡村医药, 2014, 21(19):48-49.
[32] 修双玲, 王立, 贾克宝,等. 糖尿病患者应用他汀药物致肌病8例报告[J]. 山西医科大学学报, 2014, 45(12):1183-1186.
[33] 赵玉芬, 王燕芬, 周淑玲. 阿托伐他汀钙片口服致肌酶升高2例[J]. 中国药业, 2014, 23(12):112.
[34] 朱明成. 他汀类药物引起相关性肌病不良反应的调查分析[J]. 中国当代医药, 2015, 22(26):180-182.
[35] 邹钒, 郑天衡, 朱鑫璞. 他汀类药物相关肌病(肌炎)1例报告[C]. 中华医学会第十八次全国神经病学学术会议论文汇编, 2015, 723.
[36] 程丽丹, 江一唱. 196例肌酸激酶异常升高病例分析[J]. 临床急诊杂志, 2016, 17(4):304-307.
[37] 江岳鑫, 娄莹, 刘玉清,等. 他汀类药物致160例肌病相关不良反应的临床分析[J]. 中华高血压杂志, 2015, 42(6):905-909.
[38] IBM Micromedex. Drug interaction[DB/OL].[2018-01-08]. http://
www.micromedexsolutions.com/micromedex2/librarian/PFDef-
39 aultActionId/evidencexpert.ShowDrugInteractionsResults.
[39] Group H C, Haynes R, Jiang L, et al.Fast Track: Editor's choice: HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-
risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes,reasons for stopping study treatment[J]. European Heart Journal, 2013, 34(17):1279-1291.
[40] Rosenson R S, Baker S K, Jacobson T A, et al.An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. Journal of Clinical Lipidology, 2014, 8(3):S58-S71.
[41] Graham D J, Staffa J D, Andrade S E, et al.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs[J]. Jama the Journal of the American Medical Association, 2004, 292(21):2585-2590.
[42] Bruckert E, Hayem G, Dejager S, et al.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J]. Cardiovasc Drugs Ther, 2005, 19(6):403-414.
[43] Pfeffer M A, Keech A, Sacks F M, et al.Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project[J]. Circulation, 2002, 105(20):2341-2346.
[44] Ridker P M, Danielson E, Fonseca FA, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. Current Atherosclerosis Reports, 2008, 11(4):243-244.
[45] Al-Jubouri M A, Briston P G, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy[J]. Bmj, 1994, 308(6928):588.
[46] Scalvini T, Marocolo D, Cerudelli B, et al.Pravastatin-associated myopathy. Report of a case[J]. Recenti Progressi in Medicina, 1995, 86(5):198.
[47] Vladutiu G D.Genetic predisposition to statin myopathy[J]. Current Opinion in Rheumatology, 2008, 20(6):648.
[48] Mancini G B J, Tashakkor A Y, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update[J]. Canadian Journal of Cardiology, 2016, 32(7):S35-S65.
[49] Patel A M, Shariff S, Bailey D G, et al.Statin Toxicity From Macrolide Antibiotic Coprescription: A Population-Based Cohort Study[J]. Annals of Internal Medicine, 2014, 46(1):156.
[50] Kashani A, Phillips C O, Foody J M, et al.Risks associated with statin therapy: a systematic overview of randomized clinical trials[J]. Circulation, 2006, 114(25):2788-2797.
[51] Melli G, Chaudhry V, Cornblath D R.Rhabdomyolysis: an evaluation of 475 hospitalized patients[J]. Medicine, 2005, 84(6):377.
[52] Robert S R, Steven K B. Statin muscle-related adverse events[DB/OL].(2017-09-22) [2018-02-07]. https://www.uptodate.com/
contents/statin-muscle-related-adverse-events.
[53] Alshekhlee A, Katirji B, Alshekhlee A, et al.Clinical perspectives of statin-induced rhabdomyolysis[J]. American Journal of Medicine, 2007, 120(12):400-409.
[54] Rosenson R S.Current overview of statin-induced myopathy[J]. American Journal of Medicine, 2004, 116(6):408-416.